CAR-T Meeting 2024 | The future of CAR-T for the treatment of lymphoma
In this video, Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, provides an insight into the future of CAR T-cell therapy for the treatment of lymphoma, including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Although CAR-T is most well-established in DLBCL, there is ongoing investigation to move CAR-T into earlier lines of therapy in all of these hematological malignancies, especially in high-risk patients. Translational and clinical research is playing a role in increasing the efficacy of CAR-T products while decreasing manufacturing time and associated toxicities. Prof. Sureda also highlights that the development of allogeneic CAR T-cells will likely overcome some of the challenges associated with autologous CAR-T. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
